Skip to main content
Allison Kurian, MD, Oncology, Palo Alto, CA

Allison Walsh Kurian MD MSc

Oncology•Palo Alto, CA

Breast Cancer, Cancer Genetics/Cancer Risk Assessment

Professor, Medicine - Oncology and Epidemiology & Population Health, Stanford University School of Medicine

Join to view full profile

  • 300 Pasteur DrPalo Alto, CA 94305

  • Phone+1 650-723-4000

Dr. Kurian is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Kurian's full profileAlready have an account?

Education & Training

  • Stanford University School of Medicine
    Stanford University School of MedicineM.Sc., 2004 - 2006
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2002 - 2003
  • Mass General Brigham/Massachusetts General Hospital
    Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2002
  • Harvard Medical School
    Harvard Medical SchoolClass of 1999
  • Stanford University
    Stanford UniversityB.A., 1991 - 1995

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2002 - 2027
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2017
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Association of Risk-Reducing Salpingo-Oophorectomy with Breast Cancer Risk in Women with BRCA1 and BRCA2 Pathogenic Variants  
    Mary B Daly, Sarah Colonna, Saundra S Buys, Allison W Kurian, JAMA Oncology
  • Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer—Reply  
    Allison W Kurian, Steven J Katz, JAMA
  • From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing  
    William J Gradishar, Al B Benson, Massimo Cristofanilli, Allison W Kurian, Value in Health

Lectures

  • Breast cancer treatment according to pathogenic variants in cancer susceptibility genes in a population-based cohort. 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
  • Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women’s Health Initiative. 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
  • Genetic testing and results in population-based breast cancer patients and ovarian cancer patients. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

  • From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor SequencingAugust 2018

Press Mentions

  • Beyond BRCA: Breast Cancer Genetic Risk and Treatment
    Beyond BRCA: Breast Cancer Genetic Risk and TreatmentNovember 6th, 2025
  • Nearly Half with Early-Stage Breast Cancer Extend Endocrine Therapy Beyond Five Years
    Nearly Half with Early-Stage Breast Cancer Extend Endocrine Therapy Beyond Five YearsJune 20th, 2025
  • Patients Choose Decade-Long Breast Cancer Treatment: A New Trend in Oncology
    Patients Choose Decade-Long Breast Cancer Treatment: A New Trend in OncologyJune 9th, 2025

Grant Support

  • Virtual solutions to reduce gaps in genetic risk evaluation and management in families with hereditary cancer syndromes: The Genetic Information and Family Testing (GIFT 2) StudyUNIVERSITY OF MICHIGAN AT ANN ARBOR2026–2031
  • Personalizing genetic test results management and outcomes after diagnosis of cancer: the Georgia-California SEER Genelink StudySTANFORD UNIVERSITY2024–2029
  • A population-based virtual solution to reduce gaps in genetic risk evaluation and management in families at high risk for hereditary cancer syndromes: The Georgia-California GeneLINK TrialUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Allison Kurian, Dr. Allison Kurian, MD, Dr. A Kurian, Dr. Allison Walsh Kurian